Afficher la notice abrégée

Use of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study

dc.rights.licenseopenen_US
dc.contributor.authorHADJADJ, Jerome
dc.contributor.authorCANZIAN, Alice
dc.contributor.authorKARADAG, Omer
dc.contributor.authorCONTIS, Anne
dc.contributor.authorMAURIER, Francois
dc.contributor.authorSANGES, Sebastien
dc.contributor.authorSARTORELLI, Silvia
dc.contributor.authorDENIS, Laure
dc.contributor.authorDE MOREUIL, Claire
dc.contributor.authorDUREL, Cecile-Audrey
dc.contributor.authorDURUPT, Stephane
dc.contributor.authorJACHIET, Marie
dc.contributor.authorROUZAUD, Diane
dc.contributor.authorSALVARANI, Carlo
dc.contributor.authorPADOAN, Roberto
dc.contributor.authorDAGNA, Lorenzo
hal.structure.identifierBordeaux population health [BPH]
hal.structure.identifierGlobal Health in the Global South [GHiGS]
dc.contributor.authorBONNET, Fabrice
dc.contributor.authorAGARD, Christian
dc.contributor.authorMOULINET, Thomas
dc.contributor.authorHERMET, Marion
dc.contributor.authorSTERPU, Raluca
dc.contributor.authorMARIA, Alexandre Thibault Jacques
dc.contributor.authorKERAEN, Jeremy
dc.contributor.authorGUILLEVIN, Loic
dc.contributor.authorJAYNE, David
dc.contributor.authorTERRIER, Benjamin
dc.date.accessioned2022-07-15T08:53:39Z
dc.date.available2022-07-15T08:53:39Z
dc.date.issued2022-06-10
dc.identifier.issn1462-0332 (Electronic) 1462-0324 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/140494
dc.description.abstractEnOBJECTIVES: To describe the effectiveness and safety of biologics for the treatment of relapsing and/or refractory polyarteritis nodosa (PAN). METHODS: A retrospective European collaborative study was conducted in patients with PAN who received biologics for relapsing and/or refractory disease. RESULTS: Forty-two patients with PAN received a total of 53 biological courses, including TNF-alpha blockers in 15 cases, rituximab (RTX) in 18 cases, tocilizumab (TCZ) in 10 cases, and other biologics in 10 cases. TNF-alpha blockers and TCZ were mainly used for refractory diseases whereas RTX was mainly initiated for relapsing disease. After a median follow-up of 29 (8-50) months, remission occurred in 40%, partial response in 13%, treatment failure in 40% and treatment discontinuation due to severe adverse events in 7% of patients receiving TNF-alpha blockers, 50%, none, 30% and 20% of TCZ recipients, and 33%, 11%, 56% and none of the RTX recipients, respectively. No remission was noted in patients treated with other biologics. Severe adverse events were observed in 14 (28%) patients without significant differences between the 3 biologics, leading to early biologics discontinuation in only 3 cases. CONCLUSION: These results suggest that TCZ may be effective in relapsing and/or refractory PAN. Our data warrant further study to confirm these findings.
dc.language.isoENen_US
dc.subject.enPolyarteritis nodosa
dc.subject.enBiologics
dc.subject.enTocilizumab
dc.subject.enRituximab
dc.subject.enTNF-α
dc.subject.enBlocker
dc.title.enUse of biologics to treat relapsing and/or refractory polyarteritis nodosa: data from a European collaborative study
dc.typeArticle de revueen_US
dc.identifier.doi10.1093/rheumatology/keac332en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed35686919en_US
bordeaux.journalRheumatologyen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamGHIGS_BPHen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03723767
hal.version1
hal.date.transferred2023-06-29T12:33:17Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Rheumatology&rft.date=2022-06-10&rft.eissn=1462-0332%20(Electronic)%201462-0324%20(Linking)&rft.issn=1462-0332%20(Electronic)%201462-0324%20(Linking)&rft.au=HADJADJ,%20Jerome&CANZIAN,%20Alice&KARADAG,%20Omer&CONTIS,%20Anne&MAURIER,%20Francois&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée